Inovio Pharma (INO) Misses Q2 EPS by 119c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Inovio Pharmaceuticals (INO) PT Lowered to $8 at RBC Capital
August 9, 2024 6:26 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $8.00 (from $11.00) while maintaining a Sector Perform rating.
The analyst comments "Recent and newly disclosed manufacturing issues for INO-3107's CELLECTRA device push BLA submission for accelerated approval to... More



